<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
ATHE
Alterity Therapeutics
$
()


  • Alterity announces presentations of data on Parkinson's Disease, MSA

    4/17/2024 - 07:32am
  • Biotech Alert: Searches spiking for these stocks today

    4/15/2024 - 10:45am
  • Alterity Therapeutics receives A$3.9M R&D Tax Incentive refund

    3/26/2024 - 10:26am
  • Alterity Therapeutics Ltd (ADR) trading halted, news pending

    2/21/2024 - 17:41pm
  • Alterity Therapeutics says Phase 2 DMC recommends continuation of trial

    2/6/2024 - 07:32am
  • Alterity Therapeutics expects preliminary data from ATH434-202 study in 1H24

    1/22/2024 - 07:29am
  • Alterity Therapeutics CFO Kathryn Andrews resigns, Phillip Hains succeeds

    12/21/2023 - 05:23am
  • Biotech Alert: Searches spiking for these stocks today

    12/7/2023 - 11:14am
  • Biotech Alert: Searches spiking for these stocks today

    12/6/2023 - 11:17am
  • Alterity Therapeutics reports efficacy data for ATH434 in Parkinson's Disease

    12/4/2023 - 07:27am
  • Alterity Therapeutics announces presentation of biomarker data in MSA

    11/27/2023 - 07:31am
  • Alterity Therapeutics presents data on novel mechanisms of ATH434

    11/16/2023 - 07:29am
  • Alterity Therapeutics completes enrollment in ATH434-201 Phase 2

    11/8/2023 - 07:27am
  • Alterity Therapeutics says ATH434-202 trial 'enrolling according to plan'

    10/30/2023 - 07:28am
  • Alterity Therapeutics closes screening for ATH434-201 Phase 2 trial

    10/30/2023 - 07:27am
dynamic_feed Breaking News